Cargando…
Oral Treatment of Central Serous Chorioretinopathy Patients Using Propranolol Tablets
Purpose: To evaluate the pharmacological effects of propranolol treatment of patients with central serous chorioretinopathy (CSCR) over 4 months. Results: Among the 89 male and 31 female patients, the mean BCVA decreased to 0.42 ± 0.08 logMAR during CSCR attacks. Oral propranolol showed good effecti...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690838/ https://www.ncbi.nlm.nih.gov/pubmed/33114121 http://dx.doi.org/10.3390/ph13110336 |
_version_ | 1783614159827501056 |
---|---|
author | Chen, Li-Chai Ma, Jui-Wen Shieh, Po-Chuen Horng, Chi-Ting |
author_facet | Chen, Li-Chai Ma, Jui-Wen Shieh, Po-Chuen Horng, Chi-Ting |
author_sort | Chen, Li-Chai |
collection | PubMed |
description | Purpose: To evaluate the pharmacological effects of propranolol treatment of patients with central serous chorioretinopathy (CSCR) over 4 months. Results: Among the 89 male and 31 female patients, the mean BCVA decreased to 0.42 ± 0.08 logMAR during CSCR attacks. Oral propranolol showed good effectiveness in reducing CSCR signs after at least 4 months of treatment. The final BCVA of the patients in groups 1 and 2 was 0.09 ± 0.01 and 0.19 ± 0.03 logMAR, respectively (p < 0.05). Moreover, the mean complete remission time in groups 1 and 2 was 1.9 and 3.5 months, respectively (p < 0.05), while the “success” rate in groups 1 and 2 was 95.0% (57/60) and 78.3% (47/60), respectively (p < 0.05). The recurrence rate in groups 1 and 2 was 5.3% (3/57) and 25.5% (12/47) after a further 5 months of follow-up, respectively (p < 0.05). Materials and Methods: One hundred and twenty patients were enrolled and randomly divided into two groups that both underwent a visual acuity test and optical coherence tomography (OCT) scanning, between April and December 2017. The 60 patients in group 1 were requested to take propranolol for 4 months, while the other 60 subjects (group 2) received placebo therapy during the same period. The best-corrected visual acuity (BCVA) of every volunteer and an OCT image of each patient were checked and recorded at the beginning of the study and each week thereafter. If the signs of CSCR disappeared completely from the OCT scans, the case was considered a “success” and treatment stopped at once. However, the “success” subjects were further evaluated in follow-ups throughout the next 5 months to determine the rate of recurrence in groups 1 and 2. The time of total complete remission of CSCR from the OCT scans was also measured in groups 1 and 2. Conclusion: CSCR patients revealed an excellent prognosis and success rate of 95.0% after taking propranolol. The treatment was able to enhance subretinal fluid (SRF) absorption, shorten the time to total complete remission, and significantly decrease CSCR recurrence. As such, we suggest that taking propranolol may be an alternative and viable choice for CSCR patients, given that the new method was shown to be safe, cheap, effective, well tolerated and convenient. |
format | Online Article Text |
id | pubmed-7690838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76908382020-11-27 Oral Treatment of Central Serous Chorioretinopathy Patients Using Propranolol Tablets Chen, Li-Chai Ma, Jui-Wen Shieh, Po-Chuen Horng, Chi-Ting Pharmaceuticals (Basel) Article Purpose: To evaluate the pharmacological effects of propranolol treatment of patients with central serous chorioretinopathy (CSCR) over 4 months. Results: Among the 89 male and 31 female patients, the mean BCVA decreased to 0.42 ± 0.08 logMAR during CSCR attacks. Oral propranolol showed good effectiveness in reducing CSCR signs after at least 4 months of treatment. The final BCVA of the patients in groups 1 and 2 was 0.09 ± 0.01 and 0.19 ± 0.03 logMAR, respectively (p < 0.05). Moreover, the mean complete remission time in groups 1 and 2 was 1.9 and 3.5 months, respectively (p < 0.05), while the “success” rate in groups 1 and 2 was 95.0% (57/60) and 78.3% (47/60), respectively (p < 0.05). The recurrence rate in groups 1 and 2 was 5.3% (3/57) and 25.5% (12/47) after a further 5 months of follow-up, respectively (p < 0.05). Materials and Methods: One hundred and twenty patients were enrolled and randomly divided into two groups that both underwent a visual acuity test and optical coherence tomography (OCT) scanning, between April and December 2017. The 60 patients in group 1 were requested to take propranolol for 4 months, while the other 60 subjects (group 2) received placebo therapy during the same period. The best-corrected visual acuity (BCVA) of every volunteer and an OCT image of each patient were checked and recorded at the beginning of the study and each week thereafter. If the signs of CSCR disappeared completely from the OCT scans, the case was considered a “success” and treatment stopped at once. However, the “success” subjects were further evaluated in follow-ups throughout the next 5 months to determine the rate of recurrence in groups 1 and 2. The time of total complete remission of CSCR from the OCT scans was also measured in groups 1 and 2. Conclusion: CSCR patients revealed an excellent prognosis and success rate of 95.0% after taking propranolol. The treatment was able to enhance subretinal fluid (SRF) absorption, shorten the time to total complete remission, and significantly decrease CSCR recurrence. As such, we suggest that taking propranolol may be an alternative and viable choice for CSCR patients, given that the new method was shown to be safe, cheap, effective, well tolerated and convenient. MDPI 2020-10-23 /pmc/articles/PMC7690838/ /pubmed/33114121 http://dx.doi.org/10.3390/ph13110336 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chen, Li-Chai Ma, Jui-Wen Shieh, Po-Chuen Horng, Chi-Ting Oral Treatment of Central Serous Chorioretinopathy Patients Using Propranolol Tablets |
title | Oral Treatment of Central Serous Chorioretinopathy Patients Using Propranolol Tablets |
title_full | Oral Treatment of Central Serous Chorioretinopathy Patients Using Propranolol Tablets |
title_fullStr | Oral Treatment of Central Serous Chorioretinopathy Patients Using Propranolol Tablets |
title_full_unstemmed | Oral Treatment of Central Serous Chorioretinopathy Patients Using Propranolol Tablets |
title_short | Oral Treatment of Central Serous Chorioretinopathy Patients Using Propranolol Tablets |
title_sort | oral treatment of central serous chorioretinopathy patients using propranolol tablets |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690838/ https://www.ncbi.nlm.nih.gov/pubmed/33114121 http://dx.doi.org/10.3390/ph13110336 |
work_keys_str_mv | AT chenlichai oraltreatmentofcentralserouschorioretinopathypatientsusingpropranololtablets AT majuiwen oraltreatmentofcentralserouschorioretinopathypatientsusingpropranololtablets AT shiehpochuen oraltreatmentofcentralserouschorioretinopathypatientsusingpropranololtablets AT horngchiting oraltreatmentofcentralserouschorioretinopathypatientsusingpropranololtablets |